Chronic obstructive pulmonary disease may be one of the terminal end points of metabolic syndrome

Pakistan Journal of Medical Sciences

Volumn 28, Issue 3, 2012, Pages 376-379

  Helvaci, Mehmet Rami ^a   Aydin, Leyla Yilmaz ^b   Aydin, Yusuf ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b DUZCE UNIVERSITY   (Turkey)

Author keywords

Aging; Chronic obstructive pulmonary disease; Metabolic syndrome; Smoking

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF CARBOHYDRATE METABOLISM; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SMOKING; STROKE; WHITE COAT HYPERTENSION;

EID: 84861842381     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.
2. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-438.
3. Tonkin AM. The metabolic syndrome(s)? Curr Atheroscler Rep 2004;6:165-166.
4. Franklin SS, Barboza MG, Pio JR, Wong ND. Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. J Hypertens 2006;24:2009-2016.
5. Helvaci MR, Kaya H, Gundogdu M. Association of increased triglyceride levels in metabolic syndrome with coronary artery disease. Pak J Med Sci 2010;26:667-672.
6. Helvaci MR, Kaya H, Borazan A, Ozer C, Seyhanli M, Yalcin A. Metformin and parameters of physical health. Intern Med 2008;47:697-703.
7. Helvaci MR, Seyhanli M. What a high prevalence of white coat hypertension in society. Intern Med 2006;45:671-674.
8. Helvaci MR, Kaya H, Sevinc A, Camci C. Body weight and white coat hypertension. Pak J Med Sci 2009;25:916-921.
9. Celli BR. Update on the management of COPD. Chest 2008;133:1451-1462.
10. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2010. Global initiative for chronic obstructive lung disease (GOLD).
11. Ischaki E, Papatheodorou G, Gaki E, Papa I, Koulouris N, Loukides S. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest 2007;132:164-169.
12. Zhou Y, Wang C, Yao W, Chen P, Kang J, Huang S, et al. COPD in Chinese nonsmokers. Eur Respir J 2009;33:509-518.
13. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;17:106:3143-3421.
14. Clark LT, El-Atat F. Metabolic Syndrome in African Americans: implications for preventing coronary heart disease. Clin Cardiol 2007;30:161-164.
15. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251-1257.
16. Helvaci MR, Kaya H, Seyhanli M, Yalcin A. White coat hypertension in definition of metabolic syndrome. Int Heart J 2008;49:449-457.
17. del Puerto-Nevado L, Perez-Rial S, Giron-Martínez A, Peces-Barba G. Role of inflammation in the etiopathogenesis of COPD. Arch Bronconeumol 2010;46:2-7.
18. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-1482.
19. Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006;27:627-643.
20. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 2000;160:2653-2658.
21. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-339.
22. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411-415.
23. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-1259.
24. Murray CJ, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study. Lancet 1997;349:1347-1352.